Estimating the burden of vaccine preventable lower respiratory tract disease in primary care, UK: protocol for a prospective surveillance study (AvonCAP GP2).

Autor: Duncan P; Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom polly.duncan@bristol.ac.uk.; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Mears R; Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom.; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Begier E; Global Respiratory Vaccines, Medical & Scientific Affairs, Pfizer Inc, Collegeville, United States., Halvaei SR; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Southern J; Evidence Generation, Pfizer Inc, Collegeville, United States., Porter SB; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Hubler R; Evidence Generation, Pfizer Inc, Collegeville, United States., Oben G; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Qian G; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Lahuerta M; Global Respiratory Vaccines, Medical & Scientific Affairs, Pfizer Inc, Collegeville, United States., Davis T; Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom., Campling J; Vaccines Medical Affairs, Pfizer Ltd, Tadworth, United Kingdom., Christensen H; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Oliver J; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Morales-Aza B; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Pan K; EvGen Statistics, Pfizer Research and Development, Pfizer Inc, Collegeville, United States., Gray S; Evidence Generation, Pfizer Inc, Collegeville, United States., Hyams C; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Danon L; School of Engineering Mathematics and Technology, University of Bristol, Bristol, United Kingdom., Gessner BD; Global Respiratory Vaccines, Medical & Scientific Affairs, Pfizer Inc, Collegeville, United States.; West of England NIHR Clinical Research Network, Bristol, United Kingdom., Finn A; Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Hay AD; Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom.

Publikováno v: BJGP open [BJGP Open] 2024 Oct 02. Date of Electronic Publication: 2024 Oct 02.

Combined multiplex panel test results are a poor estimate of disease prevalence without adjustment for test error.

Autor: Challen R; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.; Department of Engineering Mathematics, University of Bristol, Bristol, United Kingdom., Chatzilena A; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.; Department of Engineering Mathematics, University of Bristol, Bristol, United Kingdom., Qian G; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.; Department of Engineering Mathematics, University of Bristol, Bristol, United Kingdom., Oben G; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.; Department of Engineering Mathematics, University of Bristol, Bristol, United Kingdom., Kwiatkowska R; Population Health Sciences, University of Bristol, United Kingdom.; NIHR Health Protection Unit in Behavioural Science and Evaluation, University of Bristol, United Kingdom., Hyams C; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Finn A; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Tsaneva-Atanasova K; Department of Mathematics and Statistics, University of Exeter, United Kingdom., Danon L; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.; Department of Engineering Mathematics, University of Bristol, Bristol, United Kingdom.

Publikováno v: PLoS computational biology [PLoS Comput Biol] 2024 Apr 26; Vol. 20 (4), pp. e1012062. Date of Electronic Publication: 2024 Apr 26 (Print Publication: 2024).

Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.

Autor: Hyams C; Population Health Sciences, University of Bristol, Bristol, UK. Electronic address: catherine.hyams@bristol.ac.uk., Lahuerta M; Pfizer Vaccines, Collegeville, PA, USA., Theilacker C; Pfizer Vaccines, Collegeville, PA, USA., King J; Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, UK., Adegbite D; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., McGuinness S; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., Grimes C; North Bristol NHS Trust, Bristol, UK., Campling J; Vaccines Medical Affairs, Pfizer Ltd, Surrey, UK., Southern J; Pfizer Vaccines, Collegeville, PA, USA., Pride MW; Vaccine Research and Development, Pfizer Research, NY, USA., Begier E; Pfizer Vaccines, Collegeville, PA, USA., Maskell N; Academic Respiratory Unit, University of Bristol, Bristol, UK., Oliver J; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK., Jodar L; Pfizer Vaccines, Collegeville, PA, USA., Gessner BD; Pfizer Vaccines, Collegeville, PA, USA., Finn A; Bristol Vaccine Centre, Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, UK.

Publikováno v: Vaccine [Vaccine] 2024 Mar 07; Vol. 42 (7), pp. 1599-1607. Date of Electronic Publication: 2024 Feb 08.

Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022.

Autor: Chatzilena A; These authors contributed equally to this work and share first/last authorship.; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom.; Engineering Mathematics, University of Bristol, Bristol, United Kingdom., Hyams C; These authors contributed equally to this work and share first/last authorship.; Population Health Sciences, University of Bristol, Bristol, United Kingdom.; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom., Challen R; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom.; Engineering Mathematics, University of Bristol, Bristol, United Kingdom., Marlow R; Population Health Sciences, University of Bristol, Bristol, United Kingdom., King J; Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, United Kingdom., Adegbite D; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom., Kinney J; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom., Clout M; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom., Maskell N; Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, United Kingdom., Oliver J; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom., Finn A; These authors contributed equally to this work and share first/last authorship.; Bristol Vaccine Centre, Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, United Kingdom.; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom., Danon L; These authors contributed equally to this work and share first/last authorship.; Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, United Kingdom.; Engineering Mathematics, University of Bristol, Bristol, United Kingdom.

Publikováno v: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2023 Nov; Vol. 28 (48).

Serotype Distribution and Disease Severity in Adults Hospitalized with Streptococcus pneumoniae Infection, Bristol and Bath, UK, 2006‒2022.

Autor: Hyams C, Challen R, Hettle D, Amin-Chowdhury Z, Grimes C, Ruffino G, Conway R, Heath R, North P, Malin A, Maskell NA, Williams P, Williams OM, Ladhani SN, Danon L, Finn A

Publikováno v: Emerging infectious diseases [Emerg Infect Dis] 2023 Oct; Vol. 29 (10).